policy
Regenerative medicine, including therapeutic use of stem cells
Regenerative medicine holds promise in treating a variety of diseases, yet questions remain. The AVMA supports the continued scientific development of…
policy
Guidelines for use of autogenous biologics
Autogenous biological products may provide veterinarians a unique opportunity for control of certain infectious diseases when USDA-licensed commercial…
policy
Guidelines for use of exempt biologics
State-licensed veterinarians may consider preparing biologics in their practice facility under a VCPR in unique disease situations not adequately…
policy
Development of emerging disease agent biologics
Development of emerging infectious disease biologics is essential for One Health. The AVMA supports the development of these products through…
JAVMA news
FDA extends call for treatment limit ideas
Food and Drug Administration authorities have extended a call for ideas on how to limit durations of some approved antimicrobial treatments in…
JAVMA news
In Short
Specialties proposed, ranitidine drugs contaminated, national disease list drafted
JAVMA news
The hidden ecosystem of the gut microbiome
Millions of bacteria live in the gastrointestinal tract of animals, including cats, dogs, and humans.
AVMA news
FDA approves anemia drug for cats with chronic kidney disease
Varenzin-CA1 from Elanco is the first drug for the control of nonregenerative anemia associated with chronic kidney disease in cats to receive…